Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/6/2025

Effect of Metoclopramide on Small Bowel Motility

Mechanism of Action and Effects

  • Metoclopramide acts as a D2 dopamine receptor antagonist that stimulates gastric emptying and small intestinal transit, according to the European Society of Gastrointestinal Motility, 1, 2

Clinical Applications and Limitations

  • The European Medicines Agency recommends against long-term use of metoclopramide due to risk of extrapyramidal side effects and potentially irreversible tardive dyskinesia, especially in elderly patients, with a strength of evidence considered high 1, 2, 3
  • Metoclopramide should be used with caution after bowel anastomosis as prokinetic drugs are generally not recommended in this setting, as suggested by the European Society of Gastrointestinal Motility 2

Alternative Prokinetic Agents

  • Erythromycin, a motilin agonist, may be more effective for small bowel dysmotility, particularly in cases with absent or impaired antroduodenal migrating complexes, according to the American Gastroenterological Association 3, 4
  • Azithromycin has been suggested as potentially more effective than erythromycin for small bowel dysmotility, with moderate strength of evidence 3, 4
  • Prucalopride, a selective 5-HT4 receptor agonist, has been used for constipation and appears to have fewer cardiac risks than older agents like cisapride, as recommended by the American College of Gastroenterology 3, 4
  • Octreotide, a somatostatin analogue, may be beneficial in cases of small intestinal dysmotility, especially when other treatments have failed, with low strength of evidence 3, 4